Loading…
Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.
Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.
Its first product, Papzimeos, treats recurrent respiratory papillomatosis, a rare condition where wart-like growths block the airways, and is sold to specialist hospitals. Before approval it lived on licensing deals and shares sold to investors. Randal Kirk's Third Security has long been the largest shareholder.
Moat: none (IP / patents, regulatory licence). First mover with an approved rare-disease gene therapy, but a thin, still-loss-making commercial base.
Headquarters: Germantown, Maryland, US · Founded: 1998 · Employees: 160
Size Precigen (PGEN) is a United States Health Care company (Biotechnology) with a market value of $1.60B, the 1946th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.47 on 6 Nov 2026.
Performance Over six months the shares gained 6.2%, against -13.2% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 1,875.0% over the last twelve months (peer median +21.1%); the operating margin is -46.1% (peer median -151.2%).
Valuation It trades at 6.9× forward earnings against a peer median of 49.7× (cheapest of 7).
Capital Return on invested capital runs 39.8 points below its cost of capital (9.7% WACC).
Short interest Short interest is 13.0% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $85.7M | $9.68M | $3.92M | $6.22M | $26.9M |
| Revenue growth | — | +147% | -37% | -77% | — |
| Gross profit | $76.4M | $3.59M | -$3.40M | -$4.74M | $15.8M |
| EBITDA | -$35.4M | -$103M | -$90.2M | -$82.3M | -$67.4M |
| Net income | -$158M | -$251M | -$126M | -$95.9M | -$66.4M |
| Free cash flow | -$115M | -$89.8M | -$76.8M | -$68.5M | -$70.0M |
| Capital expenditure | $1.06M | $2.00M | $8.58M | $1.54M | $4.92M |
| Total debt | $98.3M | $98.3M | $5.50M | $7.10M | $51.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Precigen PGEN | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a |
| Ultragenyx Pharmaceutical RARE | $1.52B | +22% | +16% | -64% | n/a | n/a |
| PTC Therapeutics PTCT | $5.47B | -11% | -35% | 22% | 34.8× | 8.0% |
| Intellia Therapeutics NTLA | $1.59B | -19% | +13% | -712% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGEN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -41.2% | -6.5% | lowest of 21 |
| 6-month return | +6.2% | -13.2% | 5th highest of 19 |
| Distance from 52-week high | -50.2% | -38.9% | 6th lowest of 21 |
| Revenue growth (TTM) | +1,875.0% | +21.1% | highest of 19 |
| Operating margin | -46.1% | -151.2% | 10th highest of 19 |
| Forward P/E | 6.9× | 49.7× | cheapest of 7 |
| ROIC minus cost of capital | -39.8 pp | -11.2 pp | 5th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 51.3× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 7.6× | -4.1% | +33.5% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | n/a | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | 48.2× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% | +15.0% |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 74.9× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 166.7× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | n/a | n/a | n/a |